🧫 Running Rapamycin (Sirolimus)

What this panel can settle, and by what logic

Nine markers, and one of them is a category the rest of this site does not contain: a measurement of the drug itself rather than of its consequences.

1. The whole-blood sirolimus level answers two questions at once and nothing else on the panel answers either. First, whether the product contains what it claims. Second, what exposure your dose produces in you. Both matter because the relationship is not fixed: in a real-world cohort taking low-dose rapamycin for longevity, dose-to-blood-level relationships were linear for both formulations studied, but compounded rapamycin was estimated at 31.03% of the bioavailability of the same milligram dose of the commercial product Harinath 2025. A dose number without a level is therefore not a protocol, it is a guess about absorption.
2. The Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and ApoB (Apolipoprotein B) read the most reproducible laboratory effect of the class. mTOR inhibition raises triglycerides and cholesterol, and it is the finding transplant medicine has documented longest Hands 2025. ApoB is on the panel rather than LDL alone because it counts atherogenic particles instead of estimating the cholesterol inside them, and the two diverge in precisely the metabolic state this drug can create Johannesen 2021.
3. The Complete Blood Count (CBC) with Differential reads the second most reliable one. Cytopenias are a known class effect and the platelet count is usually the first to move, which is why a baseline before the first dose is worth more than any single later value.
4. Fasting Insulin beside HbA1c (Hemoglobin A1c) catches the glucose effect in the right order. mTOR inhibition impairs insulin sensitivity with chronic exposure; fasting insulin moves months before HbA1c does, so the pair reads the trend rather than the endpoint.
5. Urinalysis, Routine is a $10 marker for a recognized class effect. Proteinuria appears in the urine before it appears anywhere in serum Hands 2025.
6. hs-CRP (High-Sensitivity C-Reactive Protein) is both the safety context for the blood count and the marker most often named as the intended benefit, which makes it the one number on the panel that could falsify the reason for taking the drug Luo 2023.

What the combination settles that no single marker does: whether an abnormal lipid or blood count belongs to your dose or to your exposure. A high triglyceride with a level at the bottom of the measurable range is a different problem from the same triglyceride with a level three times higher than the dose predicts.

What it cannot settle, and what would

It cannot tell you whether rapamycin is extending your healthspan, and no panel can. The human evidence for the longevity use is small, short and mostly uncontrolled, which is the conclusion of the review written to assess exactly that question Hands 2025. The largest dedicated trial in healthy adults reported changes in lean tissue mass and self-reported pain in women taking 10 mg weekly, and in emotional well-being and general health at 5 mg, over one year Moel 2025. Those are outcomes measured on people, not markers on a panel.

It cannot detect the adverse effects that matter most in practice, because they are not in blood. Mouth ulcers, delayed wound healing and susceptibility to infection are the commonly reported ones and every one of them is observed rather than measured Hands 2025. A panel that comes back clean while you are getting recurrent mouth ulcers has not overruled the ulcers.

It cannot give you a target range. Whole-blood trough targets exist for transplant immunosuppression and are not transferable to weekly low-dose use, where no validated therapeutic window has been established Harinath 2025. The level is useful as your own baseline and for comparing formulations, not for hitting a published number.

And it is not a substitute for a prescriber. This is a prescription immunosuppressant being used off-label. The panel is a safety instrument for somebody who has already made that decision, and it does not make the decision.

Draw conditions that decide whether the money is wasted

Four conditions. The first one is the difference between a $100 marker and a $100 number that cannot be used.

1. Draw the sirolimus level as a trough, immediately before your next dose, and write the exact hours since the last dose on the requisition. A level taken the day after a weekly dose is measuring a different point on the curve and is comparable to nothing, including your own next result. Dose-to-level relationships are only interpretable when the sampling time is fixed Harinath 2025.
2. Fast 9 to 12 hours for the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), ApoB (Apolipoprotein B), Fasting Insulin and HbA1c (Hemoglobin A1c). Triglycerides are the marker this drug moves and the marker a non-fasting draw distorts most.
3. Not within 2 weeks of an infection. This class suppresses the blood count and this panel is trying to attribute a low count to the drug; an infection moves the Complete Blood Count (CBC) with Differential and hs-CRP (High-Sensitivity C-Reactive Protein) together and makes the attribution impossible Luo 2023.
4. Take the same formulation you have been taking. Switching between commercial and compounded product between draws changes the exposure by several fold at an identical milligram dose Harinath 2025, so a level compared across a formulation change measures the pharmacy rather than you.

How you would know it answered your question, and what each pattern means next

Five results and what each one changes.

• Triglycerides and ApoB (Apolipoprotein B) up, Complete Blood Count (CBC) with Differential and Urinalysis, Routine normal: the expected finding. Address it as a lipid problem and retest the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and ApoB at 12 weeks, which is the interval at which a dietary or pharmacological lipid change has reached its plateau Johannesen 2021.
• A falling platelet count across two draws: the class effect that warrants a dose conversation rather than a wait. Recheck the Complete Blood Count (CBC) with Differential at 4 weeks, since platelet turnover is about 8 to 10 days and a trend is visible quickly.
• New protein on Urinalysis, Routine: repeat it before concluding anything, then take it to a clinician with the Comprehensive Metabolic Panel (CMP) Hands 2025.
• Fasting Insulin rising with HbA1c (Hemoglobin A1c) flat: the early half of the glucose effect. Recheck both at 12 weeks; HbA1c reflects roughly the preceding 3 months, so a shorter interval reads the old value.
• A sirolimus level far below what the dose predicts: suspect the product before suspecting yourself, particularly with a compounded formulation Harinath 2025. Far above it means the interval is wrong for your absorption, which is the single most actionable thing this panel can return.

And the falsification: if hs-CRP (High-Sensitivity C-Reactive Protein) does not fall and nothing else moves across a year, the honest reading is that the protocol is not doing anything measurable in you Hands 2025.

Sources read for these sections

• Hands JM, et al. What is the clinical evidence to support off-label rapamycin therapy in healthy adults?. Aging (Albany NY) 2025 · PMID 40778880
• Moel M, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025 · PMID 40188830
• Harinath G, et al. The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals. GeroScience 2025 · PMID 39873920
• Johannesen CDL, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology 2021 · PMID 33736827
• Luo H, et al. A Practical Guide to Adjust Micronutrient Biomarkers for Inflammation Using the BRINDA Method. Journal of Nutrition 2023 · PMID 36792034